Agios Pharma (AGIO) Misses Q2 EPS by 4c

Agios Pharma (NASDAQ: AGIO) reported Q2 EPS of ($1.69), $0.04 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $44.74 million versus the consensus estimate of $26.57 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Braze Inc (BRZE) PT Raised to $33 at Raymond James, 'Buy the Dip as BRZE Remains a Secular Winner'
• Tyra Biosciences reports Phase 2 data for oral bladder cancer drug